OBJECTIVE: The role of oral immunosuppressive therapy (OIT) to prevent @entity256 after percutaneous coronary intervention (PCI) and stenting is still controversial. This study evaluates the impact of oral administration of @entity229 or @entity3446 to prevent @entity256 . METHODS: We conducted a meta-analysis of trials in which PCI- @entity1 were randomized to bare metal stents (BMS) plus OIT (BMS  +  OIT group) versus BMS or drug-eluting stents alone (BMS/ @entity4743 group). Primary endpoints were @entity75 revascularization and @entity583 ( @entity583 ). Secondary endpoints were @entity204 , @entity583 , stent @entity715 and in-stent late lumen loss. Hazard ratio and weighted geometric mean difference [95% confidence intervals] served as summary statistics. RESULTS: Individual data of seven trials (1246 @entity1 [BMS  +  OIT, n  =  608 versus BMS/ @entity4743 , n  =  638] with 1456 @entity301 ) were merged. At a median follow-up of 360 days, BMS  +  OIT versus BMS/ @entity4743 significantly reduced the risk of revascularization (0.49 [0.24-0.98], P  =  0.04). In particular, BMS  +  OIT reduced the risk of revascularization (0.38 [0.21-0.67], P  <  0.001) and late lumen loss (-0.39  mm [-0.67,  -0.11], P  <  0.001) as compared with BMS alone. BMS  +  OIT versus BMS/ @entity4743 showed a similar risk of @entity204 / @entity583 (0.67 [0.29-1.53], P  =  0.34), @entity204 (0.82 [0.25-2.69], P  =  0.71), @entity583 (0.58 [0.24-1.39], P  =  0.22) and stent @entity715 (0.43 [0.10-1.87], P  =  0.26). CONCLUSION: In @entity1 undergoing PCI the use of BMS and oral immunosuppressive therapy reduces the risk of revascularization as compared with BMS alone but not as compared with @entity4743 alone, while these therapies display a similar risk of @entity204 / @entity583 . The advantage of adding oral immunosuppressive therapy to BMS is due to a lower risk of @entity256 as compared with BMS alone.

ORAl iMmunosuppressive therapy to prevent in-Stent rEstenosiS (RAMSES) cooperation: A XXXX -level meta-analysis of randomized trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary lesions'] @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity4743 :: ('CHEBI:37628', 'Chemical') :: ['DES'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity583 :: ('MESH:D009203', 'Disease') :: ['MI', 'death/myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity1 :: (9606,Species) :: ['patient']
